- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | BIO-WORKS TECHNOLOGIES AB: Resolutions passed at Bio-Works Technologies' annual general meeting 2026 | 1 | Cision News | ||
| 13.05. | BIO-WORKS TECHNOLOGIES AB: Bio-Works reports first quarter 2026 | 2 | Cision News | ||
| 29.04. | BIO-WORKS TECHNOLOGIES AB: Bio-Works receives order for WorkBeads 40S from contract manufacturer in Europe | 1 | Cision News | ||
| 17.04. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB announces outcome from exercise of warrants of series TO 2. Exercise period 6 of 11 | 8 | Cision News | ||
| 10.04. | BIO-WORKS TECHNOLOGIES AB: Proposed New Board Members in Bio-Works | 1 | Cision News | ||
| 01.04. | BIO-WORKS TECHNOLOGIES AB: Today is the first day of the sixth exercise period for Bio-Works Technologies AB's warrants of series TO 2 | 3 | Cision News | ||
| 01.04. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB - Business Update first quarter 2026 | 13 | Cision News | ||
| BIO-WORKS TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 06.03. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB publishes Business Update ahead of next value creation phase | 15 | Cision News | ||
| 20.02. | BIO-WORKS TECHNOLOGIES AB: Bio-Works publishes Year-end report Q4 2025 | 6 | Cision News | ||
| 17.02. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Receives Order from Returning Customer | 2 | Cision News | ||
| 19.01. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB announces outcome from exercise of warrants of series TO 2. Exercise period 5 of 11 | 5 | Cision News | ||
| 02.01. | BIO-WORKS TECHNOLOGIES AB: Business Update | 1 | Cision News | ||
| 29.12.25 | BIO-WORKS TECHNOLOGIES AB: Bio-Works Receives Two WorkBeads 100S and 100Q Orders Worth SEK 4 Million | 5 | Cision News | ||
| 15.12.25 | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB Annual General Meeting to be held on Thursday 4 of June 2026 | 2 | Cision News |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HELIX BIOPHARMA | 0,670 | 0,00 % | Helix BioPharma Corp. Announces Closing of Private Placement of Convertible Debentures | ||
| DAMORA THERAPEUTICS | 21,040 | +0,14 % | Damora Therapeutics, Inc.: Damora Therapeutics Appoints Biotechnology Leader Jennifer Jarrett as President and Chief Executive Officer; Adds Two Industry Veterans to Board of Directors | -- Ms. Jarrett brings nearly three decades of executive leadership in biotech, tech and finance -- -- Biotech leaders Dr. Cameron Turtle and Mike Landsittel appointed to Board of Directors -- -- Peter... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 254,00 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Vormatrigine Program Update | POWER1 Study in highly refractory patients with focal onset seizures did not meet its primary success measure Secondary measure, the 50% response rate, was met and seizure reduction during the second... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 35,590 | 0,00 % | Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business | Acquisition supports Servier's strategic ambition in rare neurology for patients with high unmet medical needs.Transaction includes sevasemten, a late-stage investigational treatment for... ► Artikel lesen | |
| JADE BIOSCIENCES | 16,940 | 0,00 % | Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy | ~70% IgA reductions sustained at 12 weeks after a single dose of JADE101>70% IgA reductions projected at steady state with a single subcutaneous maintenance injection every 12 weeksIgA-lowering effect... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 86,86 | -0,07 % | Weekly Buzz: AstraZeneca, JNJ Get FDA Nod; Eli Lilly To Acquire Curevo; APGE Advances Zumilokibart | NEW BRUNSWICK (dpa-AFX) - This week in the biotech space, there were regulatory approvals across the U.S. and Europe, collaborations, acquisitions, and positive data readouts spanning multiple... ► Artikel lesen | |
| ADMA BIOLOGICS | 7,970 | 0,00 % | ADMA BIOLOGICS, INC. - 8-K, Current Report | ||
| SUMMIT THERAPEUTICS | 14,755 | -0,10 % | All You Need to Know About Summit Therapeutics (SMMT) Rating Upgrade to Buy | ||
| ERASCA | 11,970 | 0,00 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,315 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports First Quarter Financial Results and Provides Business Update | Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predictable... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 23,720 | +0,13 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing | - Repurchase of lorundrostat royalty obligation in Tanabe license agreement for $200 million upfront and up to $100 million once certain commercial milestones are met - - $500 million committed... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 59,28 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease | - A pioneering investigational oral prophylactic approach designed to kill Lyme-infected ticks before disease transmission - IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals... ► Artikel lesen | |
| RELAY THERAPEUTICS | 13,520 | 0,00 % | Relay Therapeutics Shares Jump 18% | ||
| BEAM THERAPEUTICS | 29,370 | -0,10 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| TANGO THERAPEUTICS | 20,190 | -0,15 % | Tango Therapeutics, Inc.: Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
Das Unternehmen BIO-WORKS TECHNOLOGIES AB kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -1,50 % bei einem Aktienkurs von 0,329 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIO-WORKS TECHNOLOGIES AB finden Sie auf Wallstreet Online.